A Mixed-Methods Study on the Responsiveness of the COmprehensive Score for Financial Toxicity (COST) among people with Multiple Myeloma
Authors:
Preprint
- 13 April 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose Financial toxicity is a contributor to the psychosocial burden of cancer care. There is no consensus measure of financial toxicity, however, recent studies have adopted the COmprehensive Score for financial Toxicity (COST). Despite its growing popularity, data on the responsiveness to change of the COST are lacking. To address this gap in the literature, we performed a sequential mixed-methods study of people with multiple myeloma.Methods In the quantitative phase of the study, we collected COST scores at two time points approximately 8 weeks apart from 72 patients. In the qualitative phase, we conducted semi-structured interviews with a subset of 12 patients who reported the largest changes in COST scores. The qualitative data were analyzed using a deductive coding scheme developed using the Framework Method in the context of a commonly cited conceptual model of financial toxicity.Results The median absolute change in COST scores was 4 points (IQR 2–6). Only 13% of the sample had the same COST scores at both assessments; 38% had an improved score and 50% had a worsened score. Only, seven of the twelve patients (58%) interviewed reported changes to one or more of the constructs in the conceptual model of financial toxicity. Most commonly, changes to out-of-pocket costs were reported (5/12). Changes to non-medical expenses (n = 2) and subjective financial distress without changes to objective financial burden (n = 2) were also reported.Conclusion Additional research is needed to explicate changes in COST scores over time.Keywords
All Related Versions
- Version 1, 2023-04-13, Research Square
- Published version: JCO Oncology Practice, 20 (6), 835.
This publication has 16 references indexed in Scilit:
- Financial Toxicity During Breast Cancer Treatment: A Qualitative Analysis to Inform Strategies for MitigationJCO Oncology Practice, 2021
- Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort StudyJCO Oncology Practice, 2021
- The COmprehensive Score for financial Toxicity in China: Validation and ResponsivenessJournal of Pain and Symptom Management, 2021
- Delivery of Financial Navigation Services within National Cancer Institute-Designated Cancer CentersJNCI Cancer Spectrum, 2021
- Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsThe Oncologist, 2021
- Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of lifeAnnals of Oncology, 2020
- Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implicationsAnnals of Oncology, 2019
- Financial Hardships Experienced by Cancer Survivors: A Systematic ReviewJNCI: Journal of the National Cancer Institute, 2016
- Grading financial toxicity based upon its impact on health-related quality of life (HRQol).Journal of Clinical Oncology, 2015
- Standards for Reporting Qualitative ResearchAcademic Medicine, 2014